Misoprostol (Cytotec®)

Selected References:

- Abdel-Aleem H, et al. 2003. The pharmacokinetics of the prostaglandin E1 analogue misoprostol in plasma and colostrum after postpartum oral administration. Eur J Obstet Gynecol Reprod Biol; 108(1):25-8.
- Abdelshafy A, et al. 2019. Sublingual vs vaginal misoprostol for completion of first trimester missed abortion: a randomised controlled trial. Eur J Contracept Reprod Health Care 12: 1-6.
- Ameri A, et al. 2024. Effect of misoprostol versus oxytocin on delivery outcomes after labour induction in pregnant women: A systematic review and meta-analysis of randomized controlled trials. Eur J Obstet Gynecol Reprod Biol. 292:75-88.
- Auffret M, et al. 2016. Misoprostol exposure during the first trimester of pregnancy: Is the malformation risk varying depending on the indication? Eur J Obstet Gynecol Reprod Biol; 207:188-192.
- Bernard N, et al. 2013. Continuation of pregnancy after first-trimester exposure to mifepristone: an observational prospective study. BJOG; 120:568-575.
- Bord I, et al. 2014. Misoprostol treatment for early pregnancy failure does not impair future fertility. Gynecol Endocrinol; 30(4):316-9.
- Brasil R, et al. 2000. Misoprostol and congenital anomalies. Pharmacoepidemiol Drug Saf; 9(5):401-3.
- Brown SE, et al. 2001. Vaginal misoprostol enhances intrauterine insemination. Hum Reprod 2001; 16(1):96-101.
- Coelho KE, et al. 2000. Misoprostol embryotoxicity: clinical evaluation of fifteen patients with arthrogryposis. Am J Med Genet; 95(4):297-301.
- da Silva Dal Pizzol T, et al. 2006. Prenatal exposure to misoprostol and congenital anomalies: systematic review and meta-analysis. Reprod Toxicol; 22(4):666-71.
- Dal Pizzol Tda S, et al. 2008. Exposure to misoprostol and hormones during pregnancy and risk of congenital anomalies. Cad Saude Publica; 24(6):1447-53.
- Genest DR, et al. 1999. Terminal transverse limb defects with tethering and omphalocele in a 17 week fetus following first trimester misoprostol exposure. Clin Dysmorphol; 8(1):53-8.
- Gonzalez CH, et al. 1993. Limb deficiency with or without Möbius sequence in seven Brazilian children associated with misoprostol use in the first trimester of pregnancy. Am J Med Genet; 47(1):59-64.
- Gonzalez CH, et al. 1998. Congenital abnormalities in Brazilian children associated with misoprostol misuse in first trimester of pregnancy. Lancet; 351(9116):1624-7.
- Holmes LB, et al. 2018. Malformations attributed to the process of vascular disruption. Birth Defects Res; 110(2):98-107.
- Kandahari N, et al. 2023. Fetal heart rate patterns and the incidence of adverse events after oral misoprostol administration for cervical ripening among low-risk pregnancies. J Matern Fetal Neonatal Med. 36(1):2199344.
- Kim C, et al. 2017. Medical treatments for incomplete miscarriage. Cochrane Database Syst Rev; 1(1):CD007223.
- Orioli IM, Castilla EE. 2000. Epidemiological assessment of misoprostol teratogenicity. BJOG; 107(4):519-23.
- Ozbasli E, et al. 2022. Labor induction with intravaginal misoprostol versus spontaneous labor: maternal and neonatal outcomes. Biomed Res Int. 2022:2826927.
- Pastuszak AL, et al. 1998. Use of misoprostol during pregnancy and Möbius' syndrome in infants. N Engl J Med; 338(26):1881-5.
- Patel F, Cusack J. 2019. Möbius sequence with central hypoventilation in a neonate after failed elective medical termination of pregnancy. Arch Dis Child Fetal Neonatal Ed; 104(1):F49.
- Pfizer Laboratories Div Pfizer Inc. Last updated July 9, 2021. Cytotec drug label. Source: National Library of Medicine. Available at

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4ab12da7-5731-4e06-bf1c-bc3f2e711f12.

- Schuler L, et al. 1999. Pregnancy outcome after exposure to misoprostol in Brazil: a prospective controlled study. Reprod Toxicol; 13:147-151.
- Shimizu T, et al. 1992. Prostaglandin E1, E2, and F2 alpha in human milk and plasma. Biol Neonate; 61:222–5.
- Song J. 2000. Use of misoprostol in obstetrics and gynecology. Obstet Gynecol Surv; 55(8):503-10.
- van Look PF, von Hertzen H. 1995. Misoprostol and birth defects. BMJ; 310(6972):128.
- Vargas FR, et al. 2000. Prenatal exposure to misoprostol and vascular disruption defects: a case-control study. Am J Med Genet; 95(4):302-6.
- Vauzelle C, et al. 2013. Birth defects after exposure to misoprostol in the first trimester of pregnancy: Prospective follow-up study. Reprod Toxicol; 36:98-103.
- Vendramini-Pittoli S, et al. 2013. Clinical findings in children with congenital anomalies and misoprostol intrauterine exposure: a study of 38 cases. J Pediatr Genet. 2013 Dec;2(4):173-80.
- Vogel D, et al. 2004. Misoprostol versus methylergometrine: pharmacokinetics in human milk. Am J Obstet Gynecol; 191:2168-73.
- Yip SK, et al. 2000. Misoprostol's effect on uterine arterial blood flow and fetal heart rate in early pregnancy. Obstet Gynecol; 95(2):232-5.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at MotherToBaby.org.

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, May 1, 2024.

Misoprostol (Cytotec®)

Selected References:

- Affendi Raja RA, et al. 2022. Review of recent evidence on the management of heartburn in pregnant and breastfeeding women. BMC Gastroenterology, 22:219-229.
- Courtney TP, et al. 1988. Excretion of famotidine in breast milk. Br J Clin Pharmacol, 626:639P.
- Garbis H, et al. 2005. Pregnancy outcome after exposure to ranitidine and other H2-blockers. A collaborative

study of the European Network of Teratology Information Services. Reprod Toxicol, 19:453-458.
- Hagemann, TM, 1998. Gastrointestinal medications and breastfeeding. Journal of Human Lactation, 14(3):259–262.
- Kallen B, 1998. Delivery outcome after the use of acid-suppressing drugs in early pregnancy with special reference to omeprazole. Journal of Obstetrics and Gynecology, 105:877-881.
- Magee LA, et al.1996. Safety of first trimester exposure to histamine H2 blockers. A prospective cohort study. Dig Dis Sci, 41(6):1145-1149.
- Matok I, et al. 2010. The safety of H (2)-blockers use during pregnancy. J Clin Pharmacol, 50(1):81-87.
- Orenstein SR, Shalaby TM, Devandry SN, et al. 2003. Famotidine for infant gastro-oesophageal reflux: A multi-centre, randomized, placebo-controlled, withdrawal trial. Aliment Pharmacol Ther, 7(9):1097-107.
- Savarino V, et al. 1988. Famotidine has no significant effect on gonadal function in man. Gastroenterol Clin Biol, 12:19-22.
- Wang X, et al. 2011. Pharmacokinetics of famotidine in pregnant women. Am J Obstet Gynecol., 204: 72-73.
- Yitshak-Sade M, et al. 2016. Prenatal exposure to H2 blockers and to proton pump inhibitors and asthma development in offspring. J Clin Pharmacol, 56(1):116-123.

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, May 1, 2024.

Misoprostol (Cytotec®)

Selected References:

- Anghelache M, et al. 2022. Multiple sclerosis in pregnancy- current neurological considerations. Romanian Journal of Pediatrics, 71(2):55-59.
- Novartis Pharmaceuticals Corporation. 2022. Mayzent Drug Label, Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=44492772-5aed-4627-bd85-e8e89f308bb3
- Ruggieri S, et al. 2022. Ponesimod in the treatment of relapsing forms of multiple sclerosis: a update on the emerging clinical data. Degenerative Neurological and Neuromuscular Disease, 12:61-73.

- Sabsabi S, et al. 2023. Clinical evaluation of siponimod for the treatment of secondary progressive multiple sclerosis: pathophysiology, efficacy, safety, patient acceptability, and adherence. Patient Preference and Adherence, 16:1307–1319.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at MotherToBaby.org.

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, May 1, 2024.

Misoprostol (Cytotec®)

Selected References:

- Akinosoglou K, et al. 2023. COVID-19 Pharmacotherapy in Pregnancy: A Literature Review of Current Therapeutic Choices. Viruses. 15(3): 787.
- Aleissa MM, et al. 2021. New perspectives on antimicrobial agents: Remdesivir treatment for COVID-19. Antimicrob Agents Chemother. 38:248-251.
- Al-Kuraishy HM, et al. 2023. Pregnancy and COVID-19: high or low risk of vertical transmission. Clin Exp Med. 23(4):957-967.
- Anderson J, et al. 2020. The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: A case report. Case reports in women's health, 27, e00221.
- Arbabzadeh T, et al. 2023. Remdesivir in pregnant women with moderate to severe coronavirus disease 2019 (COVID-19): a retrospective cohort study. Clin Exp Med. 23(7):3709-3717.
- Budi, DS, et al. 2022. Remdesivir for pregnancy: A systematic review of antiviral therapy for COVID-19. Heliyon, ***8***(1), e08835.
- Bertrand K, et al. 2024. Concentrations of remdesivir and GS-441524 in human milk from lactating individuals diagnosed with COVID-19. Pediatric research. 10.1038/s41390-024-03053-2.
- Burwick RM, et al. 2021. Compassionate Use of Remdesivir in Pregnant Women With Severe Coronavirus Disease 2019. Clin Infect Dis. 6;73(11):e3996-e4004
- Cheema R, et al. 2023. Protecting Breastfeeding during the COVID-19 Pandemic. Am J Perinatol. 40(3):260-266.

- Chen M, et al. 2023. Vaccination and treatment options for SARS-CoV2 infection affecting lactation and breastfeeding. Seminars in fetal & neonatal medicine. 28(1) 101425.
- Clinical Solutions: Remdesivir monograph. Revised 5/7/2020. https://www.elsevier.com/__data/assets/pdf_file/0008/996767/Remdesivir-Drug-Monograph_28MAY2020.pdf
- Di Gennaro, et al. 2023. Efficacy and safety of therapies for COVID-19 in pregnancy: a systematic review and meta-analysis. BMC Infect Dis. 23(1):776.
- Dornemann J, et al. 2017. First newborn baby to receive experimental therapies survives Ebola virus disease. J Infect Dis, 215:171–4.
- FDA's approval of Veklury (remdesivir) for the treatment of COVID-19—the science of safety and effectiveness. 2020. Available at: https://www.fda.gov/drugs/news-events-human-drugs/fdas-approval-veklury-remdesivir-treatment-covid-19-science-safety-and-effectiveness?msclkid=172b6876c65d11ec832b5913d0d746c5. Accessed 9 Dec 2024.
- Frauenfelder C, et al. 2020. Infant with SARS-CoV-2 infection causing severe lung disease treated with remdesivir. Pediatrics. 146:e20201701.
- Gilead Sciences, Inc. 2022. Remdesivir product labeling. Available at: https://www.gilead.com/-/media/files/pdfs/medicines/covid-19/veklury/veklury_pi.pdf. Accessed 9 Dec 2024.
- Gutierrez R, et al. 2022. Remdesivir use in pregnancy during the SARS-CoV-2 pandemic, The Journal of Maternal-Fetal & Neonatal Medicine, 35(25):9445-9451.
- Jorgensen SCJ, 2021. A review of remdesivir for COVID-19 in pregnancy and lactation. J Antimicrob Chemother. 77(1):24-30.
- Jorgensen SC, et al. 2022. A review of COVID-19 therapeutics in pregnancy and lactation. Obstet Med. 15(4): 225-232.
- Lampejo T. 2021. Remdesivir for the treatment of COVID-19 in pregnancy. ***Journal of medical virology***, ***93***(7), 4114.
- Liu X, et al. 2023. Physiologically-based pharmacokinetic modeling of remdesivir and its metabolites in pregnant women with COVID-19. CPT: Pharmacometrics & systems pharmacology. 12(2) 148-153.
- Molaei E, et al. 2024. Remdesivir: treatment of COVID-19 in special populations. Naunyn Schmiedebergs Arch Pharmacol. 397(6):3829-3855.
- Mulangu S, et al. 2019. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med., 381:2293–303.
- Naqvi M, et al. 2020.Tocilizumab and Remdesivir in a Pregnant Patient With Coronavirus Disease 2019 (COVID-19), Obstetrics & Gynecology. 136(5):1025-1029.
- Nasrallah, S, et al. 2021. Pharmacological treatment in pregnant women with moderate symptoms of coronavirus disease 2019 (COVID-19) pneumonia. ***The Journal of Maternal-Fetal & Neonatal Medicine***, 1-8.
- Pierce-Williams RAM, et al. 2020. Clinical course of severe and critical COVID-19 in hospitalized pregnancies: a US cohort study. Am J Obstet Gynecol MFM; 2(3):100134.
- Sadati E, et al. 2022. Remdesivir in Breastfeeding. Tanaffos. 21(3) 261-262.
- Tavakoli N, et al. 2023. Is it possible to reduce the rate of vertical transmission and improve perinatal outcomes by inclusion of remdesivir in treatment regimen of pregnant women with COVID-19?. BMC Pregnancy Childbirth. 23(1):110.
- Wada YS, et al. 2022. Remdesivir and human milk: A case study. J Hum Lact.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at MotherToBaby.org.

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, May 1, 2024.

Misoprostol (Cytotec®)

Selected References:

- Gilboa SM, et al, and the National Birth Defects Prevention Study. 2009. Use of antihistamine medications during early pregnancy and isolated major malformations. Birth Defects Res A Clin Mol Teratol 85(2): 137-150.
- Hansen C, et al. 2020. Use of antihistamine medications during early pregnancy and selected birth defects: The National Birth Defects Prevention Study, 1997-2011. Birth Defects Res. 112:1234-1252.
- Mazzotta P, et al. 1999. Treating allergic rhinitis in pregnancy. Safety considerations. Drug Saf. 20(4):361-375.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at MotherToBaby.org.

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, May 1, 2024.